Healthcare
Healthcare Investment Banking Group
Finding financial solutions across every sector of the healthcare ecosystem.
A full-service healthcare investment banking practice offering a best-in-class combination of deep sector knowledge, strong industry relationships, and broad product expertise.
Stifel’s Global Healthcare Investment Banking Group is comprised of 47 professionals covering all segments of the healthcare industry. The team, located in New York, San Francisco and London, has substantial experience in assisting companies with all types of financing and M&A assignments. The Global Healthcare Group is dedicated to building long-term relationships with its clients through senior level attention. Since the formation of the Global Healthcare Group in Q4 2010, the team have helped raise over $79.1 billion for over 225 healthcare companies in over 440 transactions. Over the same period, members of the Global Healthcare Group have advised on over 105 announced M&A transactions, including over 30 cross-border assignments.
Our team provides clients with strategic advisory and capital-raising services designed to support growth companies and their investors during all stages of their development. We offer equity and debt capital markets services, including book running leading IPOs, follow-ons, and convertible note issuances. The Global Healthcare Group is supported by M&A advisory with extensive cross-border expertise, access to private capital markets through SPACs and 144A solutions, as well as activism defense and restructuring.
Areas of Expertise
Biopharma
The biopharma sector is advancing at an unprecedented pace, driven by innovation and growth from small to large companies across all stages of development and therapeutic areas. Stifel’s Biopharma team is uniquely positioned to serve the needs of our clients in all types of financing and M&A assignments via our deep understanding of the biopharma landscape, and our extensive relationships and transaction experience.
Medtech
The medtech sector is advancing at an unprecedented pace, driven by innovation and growth from small to large companies across all medtech subsectors. Stifel’s Medtech team is uniquely positioned to serve the needs of our clients in all types of financing and M&A assignments via our deep understanding of the Medtech landscape, and our extensive relationships and transaction experience.
Healthcare Services
The healthcare services landscape is constantly shifting, driven by changes in regulations, reimbursement, and advancements in technology. Stifel’s Healthcare Services Team works to stay abreast of these changes and is ideally positioned to serve the needs of our clients in all types of financing and M&A assignments via relationships, recent mandates, and years of thought leadership a cross a board range of healthcare sub-sectors including Alternate Site, Behavioral Health, Payor Services, Pharma Services, and Physician Groups.
Healthtech
Technologies are rapidly advancing the automation of workflows across the healthcare ecosystem, the development and efficacy of treatments, and the way in which care is provided in-person and remotely. Stifel’s Healthcare Technology team brings a wealth of M&A and financing experience advising companies delivering software, digital health, data-driven, and technology-enabled solutions to providers, payors, pharmaceutical companies, and patients.
Tools & Diagnostics
The life science tools & diagnostics sector is transforming at amazing speeds. Enabled by a broad array of new technologies, our ability to better understand all facets of the human genome has improved exponentially; all the while being done at greater efficiency and dramatically reduced costs. This widening knowledge set is enabling faster and more productive drug discovery, disease diagnosis and AI-enabled prognostic clinical capabilities. Stifel’s Life Science Tools & Diagnostics team is uniquely positioned to serve the needs of our clients in all types of financing and M&A assignments via our broad domain expertise, deep understanding of the competitive landscape, and our extensive relationships and transaction experience.
Driving innovation with forward-thinking investment banking solutions.
Learn more about the GroupNotable Transactions
$ 160,000,000
Joint Bookrunner
Biopharma | June 2021
Advisor to Seller
Healthcare Services | June 2021
$ 366,000,000
Co-Manager
Medtech | April 2021
$ 98,325,000
Joint Bookrunner
Biopharma | April 2021
$ 100,912,500
Joint Bookrunner
Medtech | April 2021
$ 287,500,000
Joint Bookrunner
Biopharma | April 2021
$ 646,875,000
Joint Bookrunner
Tools & Diagnostics | April 2021
$ 550,000,000
Joint Bookrunner
Biopharma | April 2021
$ 103,500,000
Joint Bookrunner
Biopharma | March 2021
$ 50,652,000
Left Bookrunner
Biopharma | March 2021
$ 30,000,000
Joint Bookrunner
Biopharma | March 2021
$ 48,000,000
Joint Bookrunner
Biopharma | March 2021
$ 55,000,000
Joint Placement Agent
Biopharma | March 2021
$ 56,000,000
Joint Bookrunner
Biopharma | March 2021
$ 218,500,000
Joint Bookrunner
Biopharma | March 2021
$ 115,000,000
Joint Bookrunner
Healthtech | March 2021
$ 160,425,000
Joint Bookrunner
Biopharma | March 2021
$ 138,250,000
Sole Bookrunner
Medtech | March 2021
$ 90,000,000
Advisor to Squadron
Medtech | March 2021
$ 222,250,000
Joint Bookrunner
Healthtech | February 2021
$ 60,000,000
Joint Bookrunner
Healthtech | February 2021
$ 2,200,000,000
Co-Manager
Healthcare Services | February 2021
$ 150,000,000
Joint Bookrunner
Healthtech | February 2021
$ 42,000,000
Sole Bookrunner
Medtech | February 2021
$ 117,000,000
Joint Bookrunner
Biopharma | February 2021
$ 264,500,000
Joint Bookrunner
Biopharma | February 2021
$ 203,439,942
Joint Bookrunner
Biopharma | February 2021
Capital Markets Advisor
Biopharma | February 2021
£ 40,000,000
Sole Placement Agent
Biopharma | February 2021
$ 74,500,000
Left Bookrunner
Biopharma | February 2021
$ 70,000,000
Joint Placement Agent
Healthtech | February 2021
$ 129,375,000
Joint Bookrunner
Biopharma | January 2021
$ 168,000,000
Joint Bookrunner
Biopharma | January 2021
$ 103,500,000
Joint Bookrunner
Biopharma | January 2021
$ 264,000,000
Joint Bookrunner
Healthcare Services | January 2021
$ 555,450,000
Joint Bookrunner
Biopharma | December 2020
$ 149,500,000
Joint Bookrunner
Tools & Diagnostics | December 2020
$ 200,000,000
Joint Bookrunner
Biopharma | December 2020
$ 345,080,500
Joint Bookrunner
Biopharma | December 2020
$ 312,225,000
Joint Bookrunner
Tools & Diagnostics | December 2020
$ 750,000,000
Joint Bookrunner
Tools & Diagnostics | December 2020
$ 277,725,000
Joint Bookrunner
Biopharma | December 2020
$ 1,863,000,000
Joint Bookrunner
Tools & Diagnostics | November 2020
$ 81,176,464
Joint Bookrunner
Biopharma | November 2020
$ 345,000,000
Lead Manager
Medtech | October 2020
$ 104,796,260
Left Bookrunner
Medtech | October 2020
$ 1,898,938,296
Joint Financial Advisor
Biopharma | October 2020
$ 2,128,500,000
Lead Manager
Medtech | October 2020
$ 200,000,000
Joint Bookrunner
Biopharma | September 2020
$ 277,761,104
Joint Bookrunner
Biopharma | September 2020
$ 267,696,966
Joint Bookrunner
Biopharma | September 2020
$ 963,470,000
Joint Bookrunner
Biopharma | August 2020
$ 140,000,000
Advisor to Seller
Biopharma | August 2020
$ 135,000,000
Advisor to Buyer
Biopharma | July 2020
$ 445,000,000
Financial Advisor
Biopharma | July 2020
$ 209,000,000
Joint Bookrunner
Biopharma | July 2020
$ 80,000,000
Lead Placement Agent
Biopharma | July 2020
$ 120,000,000
Joint Bookrunner
Biopharma | July 2020